Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Seagen Inc.

Keeping Track: New Uses For Opdivo, Trodelvy; Nextstellis Introduces A Novel Estrogen

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

A Hundred Drugs Contend: Chinese Biopharma Gains US Foothold

Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.

China Trade

AACR Round-Up: Zentalis, Pieris, Hookipa And Eli Lilly

Zentalis outlines promising antitumor activity associated with its WEE1 inhibitor, Phase II trials are planned for Pieris Pharmaceuticals’ fusion protein in HER2-positive cancers, while HPV-positive cancers are being targeted by Hookipa’s immunotherapeutics in arenavirus vectors, and Eli Lilly is planning early-stage clinical trials with its next-generation KRAS inhibitor.

Cancer Clinical Trials

MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase

Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.

Launches Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alpine Biosciences
    • Biomira
    • Oncothyreon, Inc.
    • Cascadian Therapeutics, Inc.
    • Seattle Genetics, Inc.
UsernamePublicRestriction

Register